ACAD
37.16
+0.17
+0.46%
AEMD
0.975
+0.005
+0.4639%
APRI
1.908
+0.118
+6.6145%
ARNA
27.58
+0.73
+2.72%
ATEC
3.85
+0.08
+2.12%
CNAT
5.11
+0.01
+0.20%
CRXM
0.137
-0.018
-11.71613%
CYTX
0.47
0.00
+0.06%
DXCM
44.09
-0.9
-2.00%
GNMK
8.07
-0.04
-0.49%
HALO
17.84
+0.1
+0.56%
ILMN
206.827
+0.347
+0.1679%
INNV
0.087
+0.001
+0.578%
INO
6.35
+0.11
+1.76%
ISCO
1.55
-0.12
-7.19%
ISIS
57.56
0.00
0.00%
LGND
142.315
+0.165
+0.116%
LPTN
2.93
-2.93
-100.00%
MBVX
0.73
0.00
-0.03%
MEIP
2.39
+0.06
+2.58%
MNOV
6.54
-0.08
-1.21%
MRTX
14.1
-0.15
-1.05%
MSTX
0.13
-0.01
0.00%
NBIX
60.25
-0.62
-1.02%
NUVA
53.74
+0.03
+0.06%
ONCS
1.2
-0.01
-0.8512%
ONVO
1.49
-0.03
-1.97%
OREX
1.94
+0.05
+2.65%
OTIC
3.425
-0.05
-1.439%
QDEL
41.49
+0.13
+0.31%
RCPT
231.96
0.00
0.00%
RGLS
1.3
-0.02
-1.52%
RMD
78.66
+0.24
+0.31%
SCIE
0
0.00
0.00%
SPHS
2.278
-0.002
-0.0790%
SRNE
2.9
+0.05
+1.75%
TROV
0.909
+0.119
+15.1013%
VICL
2.431
-0.099
-3.913%
VOLC
18
0.00
0.00%
ZGNX
38.3
+0.2
+0.52%
ACAD
37.16
+0.17
+0.46%
AEMD
0.975
+0.005
+0.4639%
APRI
1.908
+0.118
+6.6145%
ARNA
27.58
+0.73
+2.72%
ATEC
3.85
+0.08
+2.12%
CNAT
5.11
+0.01
+0.20%
CRXM
0.137
-0.018
-11.71613%
CYTX
0.47
0.00
+0.06%
DXCM
44.09
-0.9
-2.00%
GNMK
8.07
-0.04
-0.49%
HALO
17.84
+0.1
+0.56%
ILMN
206.827
+0.347
+0.1679%
INNV
0.087
+0.001
+0.578%
INO
6.35
+0.11
+1.76%
ISCO
1.55
-0.12
-7.19%
ISIS
57.56
0.00
0.00%
LGND
142.315
+0.165
+0.116%
LPTN
2.93
-2.93
-100.00%
MBVX
0.73
0.00
-0.03%
MEIP
2.39
+0.06
+2.58%
MNOV
6.54
-0.08
-1.21%
MRTX
14.1
-0.15
-1.05%
MSTX
0.13
-0.01
0.00%
NBIX
60.25
-0.62
-1.02%
NUVA
53.74
+0.03
+0.06%
ONCS
1.2
-0.01
-0.8512%
ONVO
1.49
-0.03
-1.97%
OREX
1.94
+0.05
+2.65%
OTIC
3.425
-0.05
-1.439%
QDEL
41.49
+0.13
+0.31%
RCPT
231.96
0.00
0.00%
RGLS
1.3
-0.02
-1.52%
RMD
78.66
+0.24
+0.31%
SCIE
0
0.00
0.00%
SPHS
2.278
-0.002
-0.0790%
SRNE
2.9
+0.05
+1.75%
TROV
0.909
+0.119
+15.1013%
VICL
2.431
-0.099
-3.913%
VOLC
18
0.00
0.00%
ZGNX
38.3
+0.2
+0.52%
Home » Archive by Category

Syndication

Medical Writer (Clinical Research) – ScienceMedia – San Diego, CA

October 13, 2017 – 8:20 am

The Medical Writer is responsible for the writing and instructional design of content that is developed into training assets for clients in the pharmaceutical…From Indeed – Fri, 13 Oct 2017 16:20:27 GMT – View all San Diego, CA jobs

Medical Writer – ScienceMedia – San Diego, CA

October 13, 2017 – 8:02 am

The Medical Writer will be working with clients in pharmaceutical and biotechnology space and will create content that primarily pertains to disease states and…From Indeed – Fri, 13 Oct 2017 16:02:29 GMT – View all San Diego, CA jobs

Manufacturing Assistant – Biomarker and Immunoassay

October 13, 2017 – 7:28 am

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality product …

Flow Quality Control Laboratory Assistant

October 13, 2017 – 7:27 am

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality product …

Flow Quality Control Laboratory Assistant

October 13, 2017 – 7:27 am

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality product …

Quality Control Associate – Flow Cytometry

October 13, 2017 – 7:24 am

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality product …

Manufacturing Associate Conjugation

October 13, 2017 – 7:19 am

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality product …

OncoSec to Host Fourth Quarter and Year End Financial Results Conference Call on October 25, 2017

October 13, 2017 – 4:00 am

SAN DIEGO, Oct. 13, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will host its fiscal fourth quarter and 2017 year-end financial results conference call on Wednesday, October 25th at 1:15 PM PT/4:15 PM ET.

To access the audio broadcast, please dial (877) 731- 1960 and enter the conference ID number: 86520374. An archived version of the presentation will be available for 90 days on the “Investors” section of OncoSec’s website: http://ir.oncosec.com/events-presentations.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or “tavo”). In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec’s lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.

CONTACT:

Investor Relations 
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com

Media Relations 
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/oncosec-to-host-fourth-quarter-and-year-end-financial-results-conference-call-on-october-25-2017-300536263.html

SOURCE OncoSec Medical Incorporated

Bio Roundup: Light For Spark, California Drug Law, IPO Queue & More

October 13, 2017 – 2:45 am

In a year of tragedies across the U.S., natural or otherwise, it seemed this week was California’s turn. Fueled by high winds, low humidity, and ample dry vegetation, fires swept through…

[[Click headline to continue reading.]]

Senior Manager/Director, Assay Development – Alere – San Diego, CA

October 13, 2017 – 12:56 am

Ten or more years of experience in the Medical Device, Diagnostics, Biotechnology, or Pharmaceutical industry, with at least 3 years’ experience management…
From Alere – Fri, 13 Oct 2017 08:56:06 GMT – View all San Diego, CA jobs